The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 18, 2025
Filed:
May. 24, 2021
Hengda Biomedical Technology Co., Ltd., Guangdong, CN;
Zexin Zhou, Guangdong, CN;
Zhongqiu Liu, Guangdong, CN;
Guochao Liao, Guangdong, CN;
Huapeng Li, Guangdong, CN;
Chao Zhang, Guangdong, CN;
Xiaoxiao Qi, Guangdong, CN;
Junlin Chen, Guangdong, CN;
Deying Yang, Guangdong, CN;
Hengda Biomedical Technology Co., Ltd., Guangzhou, CN;
Abstract
Disclosed are a SARS-COV-2 antigen polypeptide, a recombinant adeno-associated virus (rAAV) expressing the polypeptide, and a vaccine containing the virus. A sequence of the antigen polypeptide is shown in SEQ ID NO: 1 and SEQ ID NO: 2. A method for preparing the recombinant adeno-associated virus comprises co-incubating pHelper, pRep2Cap5, and an expression vector, transfecting a cell in the presence of polyethyleneimine as a transfection reagent; culturing the cell, then collecting the cell by centrifugation, performing lysis and purification to obtain a purified liquid comprising the recombinant adeno-associated virus. The rAAV is delivered and expressed in vivo to produce a fusion antigen polypeptide, induces the production of serum neutralizing antibodies, which have a neutralizing titer to the novel SARS-COV-2 coronavirus and are expressed continuously; the rAAV composition can be used to immunize humans against the novel coronavirus pneumonia COVID-19.